EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

An engineered Accum‐E7 protein‐based vaccine with dual anti‐cervical cancer activity

Jean-Pierre Bikorimana, Jamilah Abusarah, Marina Gonçalves, Roudy Farah, Wael Saad, Sebastien Talbot, Daniela Stanga, Simon Beaudoin, Sebastien Plouffe, Moutih Rafei iD

Cancer Science · 2024-04 · 115 (4) · 1102-1113

DOI: 10.1111/cas.16096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 29.01.2024. Verfasst von Jean-Pierre Bikorimana und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Infectious Diseases and Immunology, Université de Montréal, Montréal, Quebec, Canada. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Vaccines, Cancer Vaccines, Papillomavirus Infections. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Defence Therapeutics, Defense Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Worldwide prevalence of cervical cancer decreased significantly with the use of human papilloma virus (HPV)‐targeted prophylactic vaccines. However, these multivalent antiviral vaccines are inert against established tumors, which leave patients with surgical ablative options possibly resulting in long‐term reproductive complications and morbidity. In an attempt to bypass this unmet medical need, we designed a new E7 protein‐based vaccine formulation using Accum™, a technology platform designed to promote endosome‐to‐cytosol escape as a means to enhance protein accumulation in target cells. Prophylactic vaccination of immunocompetent mice using the Accum‐E7 vaccine (aE7) leads to complete protection from cervical cancer despite multiple challenges conducted with ascending C3.43 cellular doses (0.5‐, 1.0‐, and 2.0 × 10 6 cells). Moreover, the humoral response induced by aE7 was higher in magnitude compared with naked E7 protein vaccination and displayed potent inhibitory effects on C3.43 proliferation in vitro. When administered therapeutically to animals with pre‐established C3.43 or Tal3 tumors, the vaccine‐induced response synergized with multiple immune checkpoint blockers (anti‐PD‐1, anti‐CTLA4, and anti‐CD47) to effectively control tumor growth. Mechanistically, the observed therapeutic effect requires cross‐presenting dendritic cells as well as CD8 T cells predominantly, with a non‐negligible role played by both CD4 + and CD19 + lymphocytes. good laboratory practice (GLP) studies revealed that aE7 is immunogenic and well tolerated by immunocompetent mice with no observed adverse effects despite the use of a fourfold exceeding dose. In a nutshell, aE7 represents an ideal vaccine candidate for further clinical development as it uses a single engineered protein capable of exhibiting both prophylactic and therapeutic activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsPapillomavirus VaccinesCancer VaccinesPapillomavirus InfectionsOncogene Proteins, ViralFemaleHumansAnimalsMicePapillomavirus E7 ProteinsCD8-Positive T-LymphocytesVaccinationMice, Inbred C57BL

Stichwörter der Autor:innen

AccumE7 oncoproteincervical cancerimmune checkpoint inhibitorstherapeutic vaccine

Substanzen

Papillomavirus E7 ProteinsPapillomavirus VaccinesCancer VaccinesOncogene Proteins, Viral

Autor:innen und Institutionen

  • Department of Microbiology, Infectious Diseases and Immunology, Université de Montréal, Montréal, Quebec, Canada.
  • Department of Pharmacology and Physiology, Université de Montréal, Montréal, Quebec, Canada.
  • Department of Molecular Biology, Université de Montréal, Montréal, Quebec, Canada.
  • Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
  • Defence Therapeutics Inc., Vancouver, British Columbia, Canada.

ORCID-Profile: Moutih Rafei

Förderung

  • Defence Therapeutics
  • Defense Therapeutics

Zitieren

APA

Bikorimana, J. P., Abusarah, J., Gonçalves, M., Farah, R., Saad, W., Talbot, S., Stanga, D., Beaudoin, S., Plouffe, S., & Rafei, M. (2024). An engineered Accum‐E7 protein‐based vaccine with dual anti‐cervical cancer activity. Cancer Science, 115(4), 1102-1113. https://doi.org/10.1111/cas.16096

Vancouver

Bikorimana JP, Abusarah J, Gonçalves M, Farah R, Saad W, Talbot S, et al. An engineered Accum‐E7 protein‐based vaccine with dual anti‐cervical cancer activity. Cancer Science. 2024;115(4):1102-1113. doi:10.1111/cas.16096

BibTeX
@article{Bikorimana2024,
  author = {Bikorimana, Jean-Pierre and Abusarah, Jamilah and Gonçalves, Marina and Farah, Roudy and Saad, Wael and Talbot, Sebastien and Stanga, Daniela and Beaudoin, Simon and Plouffe, Sebastien and Rafei, Moutih},
  title = {An engineered Accum‐E7 protein‐based vaccine with dual anti‐cervical cancer activity},
  journal = {Cancer Science},
  year = {2024},
  volume = {115},
  number = {4},
  pages = {1102--1113},
  doi = {10.1111/cas.16096}
}
Kostenlos starten →